Product Liability & Toxic Torts

New Jersey Law Journal


This week we focus on pharmaceutical litigation: a ruling that failure-to-warn claims brought against generic drug makers are pre-empted by federal law, a look at why drug manufacturers who comply with FDA labeling regulations are granted a rebuttable presumption that their labeling is adequate, and some practical pointers for litigators of product-liability cases.

This premium content is reserved for New Jersey Law Journal subscribers.

Continue reading by getting started with a subscription.

Already a subscriber? Log in now

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article #1202534746688

Thank you!

This article's comments will be reviewed.